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ABSTRACT 
Background: An integrated care for the clinical management of atrial fibrillation 
patients is advocated as a holistic way to improve outcomes; the simple ABC (Atrial 
fibrillation Better Care) pathway has been proposed for this. The ABC pathway 
streamlines care as follows: ‘A’ Avoid stroke; ‘B’ Better symptom management; ‘C’ 
Cardiovascular and Comorbidity optimisation. 
Methods: We performed a post-hoc analysis of the Atrial Fibrillation Follow-up 
Investigation of Rhythm Management (AFFIRM) trial. An ‘integrated care’ approach 
was defined according to the ABC pathway. Patients fulfilling all criteria were 
categorized as the ‘ABC’ group; those not fulfilling all criteria were the ‘non-ABC’ 
group. Trial-adjudicated all-cause death, composite outcome of stroke/major 
bleeding/cardiovascular death and first hospitalization were the main outcomes. 
Results: Among the 4060 patients in the original cohort, 3169 (78.0%) had available 
data to compare integrated care (ABC; n=222; 7.0%) vs. ‘non-ABC’ (n=2947; 93.0%) 
management.  
Over a median [IQR] follow-up of 3.7 [2.8-4.6] years, Atrial fibrillation patients 
managed with integrated care (ABC group) had lower rates for all the outcomes (all 
p<0.001), compared to the non-ABC group. A Cox multivariable regression analysis 
showed that atrial fibrillation patients managed in the ABC group had a significantly 
lower risk of all-cause death (HR 0.35; 95%CI 0.17-0.75), composite outcome (HR 
0.35; 95%CI 0.18-0.68) and first hospitalization (HR 0.65, 95%CI 0.53-0.80). 
Conclusions: The simple ABC pathway allows the streamlining of integrated care 
for atrial fibrillation patients in a holistic manner and is associated with a lower risk of 
adverse outcomes (including mortality, stroke/major bleeding/cardiovascular death 
and hospitalization). 
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INTRODUCTION 
 
Atrial fibrillation has a major impact on quality of life and major adverse clinical 
events (i.e. stroke, major bleeding, cardiovascular death, hospitalizations)1,2. In the 
last decade, overall clinical management of these patients has drastically changed, 
leading to improved outcomes, particularly stroke prevention1,2. 
 
Apart from the increased risk of stroke, atrial fibrillation is also associated with 
significant mortality and more hospitalisations. Of the deaths associated with atrial 
fibrillation, only approximately 1 in 10 are stroke-related, while up to 7 in 10 are 
cardiovascular-related3–5.  Atrial fibrillation patients are afflicted by several 
comorbidities (both cardiovascular and non-cardiovascular), which may relate to the 
high cardiovascular and all-cause mortality, despite the improvements in oral 
anticoagulant (OAC) drug use5–7. Hence, more integrated pathways of atrial 
fibrillation care have been advocated, to take account of both atrial fibrillation-specific 
and non-specific clinical factors8. Such an integrated care approach significantly 
reduces cardiovascular-related hospitalizations and the risk of all-cause death9.  
 
Nevertheless, a streamlined simple approach to atrial fibrillation management is 
required. The ABC (Atrial fibrillation Better Care) pathway has been proposed as a 
possible approach to the holistic management of atrial fibrillation patients in an 
integrated manner10. The ABC pathway streamlines care as follows: ‘A’ Avoid stroke 
(with Anticoagulants); ‘B’ Better symptom management, with patient-centred 
decisions on rate or rhythm control; ‘C’ Cardiovascular and Comorbidity risk 
optimisation10.  
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We hypothesised that an integrated care approach, based on the ABC pathway, 
would significantly reduce clinically relevant outcomes (including mortality, 
stroke/major bleeding/cardiovascular death and hospitalization) in patients with atrial 
fibrillation. To test this hypothesis, we performed a post-hoc analysis of a cohort 
derived from a high-quality randomized controlled trial, the Atrial Fibrillation Follow-
up Investigation of Rhythm Management (AFFIRM) trial. 
 
 
METHODS 
 
The AFFIRM trial was a prospective randomized controlled trial investigating the 
difference in clinical outcomes of rate-control versus rhythm-control in the 
management of patients with atrial fibrillation (ClinicalTrials.Gov Identifier: 
NCT00000556), as described in detail elsewhere11,12. The present analysis is based 
on post-hoc AFFIRM database analyses, approved by the University of Missouri 
Institutional Review Board (IRB); the database was obtained from the National 
Institute of Health. The IRB for every participating centre approved the study protocol 
and all patients entered the study after providing written informed consent. The study 
was performed according to the EU Note for Guidance on Good Clinical Practice 
CPMP/ECH/135/95 and the Declaration of Helsinki. 
 
Cohort Definition and Study Exposure 
In order to verify the study hypothesis, we compared an integrated care approach, 
based on the ABC pathway, versus the standard care for atrial fibrillation patients. 
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The integrated care group (ABC group) were defined according to the criteria 
summarised in Figure 1. For the ‘A’ criterion, we considered optimal control of OAC 
therapy (vitamin K antagonist therapy only at the time of AFFIRM) as time in 
therapeutic range [TTR] ≥70%, which is optimizes thromboprophylaxis. For the ‘B’ 
criterion, we defined good symptom(s) control when the patient reported 2 or less 
symptoms among those considered in the AFFIRM trial at baseline (see Figure 1). 
For the ‘C’ criterion, only cardiovascular drugs use was available from the AFFIRM 
database, therefore we evaluated optimal pharmacological management of the main 
cardiovascular comorbidities (coronary artery disease, peripheral artery disease, 
stroke/transient ischemic attack, heart failure) according to current European 
recommendations as first line therapy13. For hypertension, we considered this as 
‘controlled’ if baseline blood pressure values were ≤140/90 mmHg.  For all the 
comorbidities considered, those optimally treated for all the conditions reported were 
defined as fulfilling the ‘C’ criterion.  
 
Patients that fulfilled all criteria for integrated care were defined as the ‘ABC’ group, 
those who did not fulfill all criteria (i.e. fulfilling only 2, 1 or none of the ABC criteria) 
were defined as the ‘non-ABC’ group. Of the original 4060 patients enrolled in the 
AFFIRM trial, we considered all anticoagulated patients with available information to 
evaluate items included in the ABC pathway criteria. 
 
Outcomes Definition 
The main outcomes for this analysis were all-cause death, the composite outcome of 
stroke/major bleeding/cardiovascular death and first hospitalization. Based on the 
original AFFIRM protocol all adverse events were reported by each investigator and 
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centrally reviewed by an independent committee11. All deaths and embolic events 
were reviewed, with deaths adjudicated according to the main cause of mortality. 
Bleeding events were centrally reviewed for descriptive purposes. Patients’ 
admission(s) to the hospital, as well as death and other major clinical adverse 
events, were reported at follow-up visits, that occurred every four months11. 
 
As secondary outcomes we considered the following: i) stroke; ii) major bleeding; iii) 
cardiovascular death; iv) first cardiovascular hospitalization; v) the occurrence of 
multiple hospitalizations; vi) total number of hospitalizations; vii) days of first 
hospitalization; and viii) total days of hospitalization. All outcomes were derived from 
the original follow-up case report forms. 
 
Statistical Analysis 
Following tests of normality, all continuous variables were reported as mean (SD, 
standard deviation) or median and interquartile range (IQR), as appropriate.  
Differences across the groups were evaluated with the t-test or Mann-Whitney U 
test, as appropriate. Categorical variables were expressed as counts and 
percentages and compared using the chi-square test. 
 
Cumulative incidence of adverse events is shown using Kaplan-Meier curves, and 
compared across the groups with the Log-Rank test. Linear, logistic and Cox 
multivariable regression models were used according to the outcome considered. 
Linear logistic regression was used to examine the total number of hospitalizations, 
days of first hospitalization and total days of hospitalization. Logistic regression was 
used for occurrence of multiple hospitalizations, with Cox regression analysis 
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employed for all the other outcomes. All regression models were adjusted for age, 
gender, diabetes mellitus, hepatic/renal disease, pulmonary disease, first atrial 
fibrillation episode, and use of aspirin. The main analyses included comparisons 
between the ABC group (i.e. integrated care) vs. the non-ABC group for the main 
trial-adjudicated outcomes. Secondary analyses considered the comparisons within 
the non-ABC care subgroup of patients with ‘part-ABC’ care (i.e. fulfilling 2 out of 3 
criteria, i.e. AB, BC, AC) against patients completely fulfilling all ABC care criteria. 
Finally, we also examined the relationship between the total number of ABC criteria 
fulfilled and occurrence of the main outcomes.  Thus, we analysed the relationship 
between incompletely fulfilling integrated care (i.e. with only 2 out of 3 ABC criteria 
fulfilled, i.e. AB, BC, AC) compared to ‘suboptimal care’ (with only 0 or 1 ABC criteria 
fulfilled), to full integrated care (i.e. ABC group).  
Additional sensitivity analyses were conducted including only patients with high 
thromboembolic risk (CHA2DS2-VASc score ≥2). A two-sided p-value <0.05 was 
considered statistically significant. All analyses were performed using SPSS v. 25.0 
(IBM, NY, USA). 
 
 
RESULTS 
 
Among the original 4060 patients enrolled in the AFFIRM trial, 3169 (78.0%) were 
anticoagulated and had available data to compare integrated care (ABC group; 
n=222; 7.0%) vs ‘non-ABC’ (n=2947; 93.0%) management approaches [Table 1]. 
Patients managed with integrated care (ABC group) were less likely to be female 
and affected by hypertension (p=0.014), comorbidities (p<0.001) and polypharmacy 
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(p<0.001). At baseline, use of aspirin was less common among atrial fibrillation 
patients in the ABC care group (p=0.001). The ABC group had lower median 
CHA2DS2-VASc score than the non-ABC care group (p<0.001) and significantly 
better TTR (p<0.001) 
 
Follow-Up Analysis 
Over a median [IQR] follow-up of 3.7 [2.8-4.6] years, patients managed with 
integrated care (ABC group) had lower rates of all-cause death (3.2% vs. 11.1%, 
p<0.001), the composite outcome (4.1% vs. 14.0%, p<0.001) and first hospitalization 
(44.6% vs. 63.4%, p<0.001), compared to the non-ABC group (Table 2). As 
secondary analyses, the ABC group also had a lower rate of major bleeding 
(p=0.004), cardiovascular death (p=0.001) and first cardiovascular hospitalization 
(p<0.001), as well as a lower rate of both multiple and total hospitalizations (both 
p<0.001). Both median number of first hospitalization days and total hospitalization 
days were lower in the ABC group (both p<0.001). 
 
Survival Analysis and Regression Models 
The cumulative risks of all-cause death, composite outcome and first hospitalization 
were significantly lower in patients managed with an integrated care approach (ABC 
group) compared to the non-ABC group [Figure 2].  For the secondary outcomes, no 
difference was found in the cumulative risk of stroke [Figure S1], but there were 
significantly lower risks for major bleeding (Log-Rank: 7.115, p=0.008), 
cardiovascular death (Log-Rank: 8.394, p=0.004) and first cardiovascular 
hospitalization (Log-Rank: 16.876, p<0.001) [Figures S2-S4]. 
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Cox multivariable regression analysis showed that use of integrated care (ABC 
group) was independently associated with a lower risk of all-cause death (hazard 
ratio [HR]: 0.35, 95% confidence interval [CI]: 0.17-0.75), the composite outcome 
(HR: 0.35, 95% CI: 0.18-0,68) and first hospitalization (HR: 0.65, 95% CI: 0.53-0.80) 
compared to non-ABC care. The ABC group was also associated with a lower risk of 
major bleeding, cardiovascular death and first cardiovascular hospitalization (Table 
3). 
 
On logistic regression analysis, an integrated care approach (ABC group) was 
associated with a lower risk of multiple hospitalizations (odds ratio: 0.38, 95% CI: 
0.26-0.56). Linear regression analysis demonstrated that the ABC approach was 
associated with significantly lower total hospitalizations (p<0.001) and total days of 
hospitalization (p=0.008) (Table 3). 
 
Number of ABC criteria fulfilled and Outcomes  
We analysed the relationship between incompletely fulfilling integrated care (i.e. with 
only 2 out of 3 ABC criteria fulfilled, i.e. AB, BC, AC) compared to suboptimal care 
(0-1 ABC criteria fulfilled), to full integrated care (i.e. ABC group). Kaplan-Meier 
curves showed progressively lower cumulative risks across the groups, from 
suboptimal care to AB, BC, AC and full integrated care (ABC group) for all-cause 
death (p<0.001) and the composite outcome (p<0.001) [Figures S5, S6].  
 
For the first hospitalization outcome, the ABC group, and the anticoagulated (i.e. AB 
and AC) groups had significantly lower risk compared to the non-anticoagulated BC 
group and suboptimal care group (p<0.001) [Figure S7]. 
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Cox regression analysis (Table 4) showed a progressively lower risk of all-cause 
death and the composite outcome from suboptimal care to AB, BC, AC and fully 
integrated care (ABC group). For the first hospitalization outcome, the three part-
ABC strategies showed a similar risk reduction, with full-integrated ABC care 
demonstrating the large relative risk reduction (42%) (Table 4). 
 
Lastly, we analysed the relationship between numbers of ABC criteria fulfilled and 
the risk of major adverse outcomes. Kaplan-Meier curves showed a progressively 
lower cumulative risk for all the main outcomes going from none to all ABC criteria 
fulfilled (all p<0.001) [Figure S8-S10]. Cox regression analysis confirmed a 
progressively lower risk with increasing number of ABC criteria for all outcomes 
(Table 5). 
 
Sensitivity Analysis 
We conducted a sensitivity analysis limited to only atrial fibrillation patients with a 
high thromboembolic risk (CHA2DS2-VASc ≥2). This analysis found that the 
integrated care approach (ABC group) was associated with a significantly lower risk 
for all the main and secondary outcomes, consistent with the main analyses (Table 
S1). 
 
 
DISCUSSION 
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In this post-hoc analysis of a clinical trial cohort of anticoagulated patients with atrial 
fibrillation, we have demonstrated that an integrated care approach based on the 
simple ABC pathway criteria was associated with a significantly lower risk of clinically 
relevant outcomes (including mortality, stroke/major bleeding/cardiovascular death 
and hospitalization), as well as lower risks of hospitalization and cardiovascular 
hospitalization.  The risk of multiple and total hospitalizations was lower, as was the 
duration of total days of hospitalization. With a progressively greater application of 
integrated care components based on the ABC pathway, there was a progressively 
lower risk of trial-adjudicated clinically relevant outcomes (including mortality, 
stroke/major bleeding/cardiovascular death and hospitalization). 
 
For the management of atrial fibrillation patients, there has necessarily been much 
focus on stroke prevention as the priority, but this only represents one component of 
an integrated or holistic approach to managing patients with atrial fibrillation.  OAC 
with vitamin K antagonists (VKA, e.g. warfarin) significantly reduces stroke and 
systemic thromboembolism (by 64%) and all-cause mortality (by 26%) when 
compared to placebo or control 14. If VKAs are used, attention to quality of 
anticoagulation control, as expressed by TTR, is crucial as TTR is a major 
determinant of major adverse outcomes15–19. In the AFFIRM trial, the only OAC used 
was warfarin, and a high TTR has been associated with improved outcomes15,20. 
Where TTR is poor, contemporary management has the option of using the non-VKA 
OACs (NOACs), given the relative efficacy, safety and convenience of these drugs 
compared to the VKAs2, although geographical differences in NOAC uptake are 
evident21 and drug adherence of these relatively short-acting OACs is important22. 
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In relation to decision-making regarding rate or rhythm control strategies, decisions 
should be made based on patient-centred and symptom-directed reasons. Rate 
control and rhythm control strategies are non-inferior in relation to adverse outcomes 
such as mortality, stroke and hospitalisation23.  The main benefit of rhythm control in 
the short-term appears to be improvement in symptoms and functional capacity24, 
although one published small trial of catheter ablation in atrial fibrillation patients with 
heart failure (CASTLE-AF) suggested a possible benefit regarding mortality and 
hospitalisations25. Presented results from the CABANA trial26 comparing drug 
therapy against catheter ablation showed non-inferiority for the primary outcome on 
an intention-to-treat analysis, although symptomatic improvement was evident in 
those randomised to catheter ablation. 
 
Nevertheless, many atrial fibrillation patients are elderly and have multiple 
comorbidities6,27,28. Indeed, the risk of cardiovascular death and all-cause death are 
common outcomes in patients with atrial fibrillation3–5,7,29.  In an analysis from the 
ROCKET-AF trial, for example, the majority of deaths related to atrial fibrillation were 
cardiovascular and related to associated comorbidities3. In the Loire Valley Atrial 
Fibrillation project, over a 2.5 years follow-up observation, 14% of patients died, with 
the majority of deaths  associated with pre-existing cardiovascular comorbidities 
rather than stroke5. Apart from proactive management of comorbidities, attention 
also needs to be focused on lifestyle modification in atrial fibrillation patients, 
including obesity, alcohol excess, regular exercise, etc30. 
 
All these aspects of atrial fibrillation patient management, including stroke 
prevention, optimization of heart rate and symptoms with rate or rhythm control, and 
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precipitants/comorbidity management have been referred to as the ‘domains of atrial 
fibrillation management’ in the 2016 European guidelines31. In a recent systematic 
review and meta-analysis, an integrated care approach as part of a holistic and 
comprehensive atrial fibrillation management plan, resulted in a significantly 
reduction in all-cause death and cardiovascular hospitalization9. The 6th Atrial 
Fibrillation Network (AFNET)/European Heart Rhythm Association (EHRA) 
consensus conference also underlined the need for developing an “integrated atrial 
fibrillation clinic”, based on atrial fibrillation nurse and dedicated cardiologist which 
could be able to implement the main atrial fibrillation management domains32.  
 
Nevertheless, approaches to provide integrated care have varying complexity8. The 
ABC pathway was proposed with the aim to provide simple guidance for the main 
components of integrated care, helping to streamline the interventions, decision-
making and optimize the patient management pathway10. The ABC pathway has 
been incorporated into our regional primary care guidance for atrial fibrillation 
detection and management issued by the West Midlands Academic Health Sciences 
Network (WMAHSN) in England (http://www.clinitecs.uk/primary-care-clinical-
pathway-for-atrial-fibrillation-detection-management). 
 
The present analyses clearly demonstrate that an integrated approach based on the 
ABC pathway was associated with reduction in mortality, stroke/major 
bleeding/cardiovascular death and hospitalization, but not stroke risk. In the 
systematic review by Gallagher and colleagues, integrated care also showed no 
significant effect on stroke occurrence9. The strong impact on the main adverse 
outcomes with the ABC pathway even in patients at high thromboembolic risk, in 
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addition to our demonstration that a progressive fulfilment of ABC components was 
associated with a progressively lower risk of adverse outcomes, substantiates and 
strengthen the concept that a holistic approach or integrated management for atrial 
fibrillation patients is associated with a significant benefit on patient outcomes. 
 
Limitations  
First, the post-hoc analysis of this study represents the main limitation, together with 
limited power to detect differences across not pre-specified groups. Second, the 
modest number of subjects and events in the integrated care (ABC) group limits the 
generalizability of our results. However, the strong reduction in risk seen despite the 
limited numbers would suggest that compliance with the ABC pathway is associated 
with a positive effect on patient outcomes. Third, patients included in the non-ABC 
group appeared to be more complex from a clinical perspective, with multiple 
comorbidities. Conversely, given the high prevalence of comorbidities in the non-
ABC group, we can speculate that full implementation of the ABC pathway may 
result in even an even greater reduction in risk. Lastly, since the original AFFIRM 
study clinical practice and guideline recommendations have evolved significantly 
over the last decade. Nonetheless, the high quality of data gathered by the original 
AFFIRM study as well as the trial-adjudicated outcomes represents a clear strength 
of the current analyses. While this study represents a first piece of evidence about 
the effective role of the simple ABC pathway in improving outcomes in atrial 
fibrillation patients, future prospective trials are needed to support and confirm our 
results and are currently ongoing. 
 
CONCLUSION 
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The simple ABC pathway allows the streamlining of integrated care for atrial 
fibrillation patients in a holistic manner and is associated with a lower risk of adverse 
outcomes (including mortality, stroke/major bleeding/cardiovascular death and 
hospitalization) in a clinical trial cohort of anticoagulated patients with atrial 
fibrillation.  
 18 
DISCLOSURES 
MP has received small consulting fee from Boehringer Ingelheim; BO has been 
consultant for Lundbeck, Amarin, Boehringer Ingelheim; DAL reports educational 
grants from Bristol-Myers Squibb and Boehringer Ingelheim, speaker activity for 
Pfizer, and consultant activity for Bristol-Myers Squibb, Bayer and Boehringer 
Ingelheim; GYHL has served as consultant for Bayer/Janssen, BMS/Pfizer, Biotronik, 
Medtronic, Boehringer Ingelheim, Microlife and Daiichi-Sankyo. Speaker for Bayer, 
BMS/Pfizer, Medtronic, Boehringer Ingelheim, Microlife, Roche and Daiichi-Sankyo. 
No fees are received personally. Other authors have no disclosures to declare.  
 19 
REFERENCES 
1.  Lip GYH, Potpara T, Boriani G, Blomström-Lundqvist C. A tailored treatment 
strategy: a modern approach for stroke prevention in patients with atrial 
fibrillation. J Intern Med. 2016;279(5):467-476. doi:10.1111/joim.12468. 
2.  Lip GYH, Freedman B, de Caterina R, Potpara TS. Stroke prevention in atrial 
fibrillation: Past, present and future comparing the guidelines and practical 
decision-making. Thromb Haemost. 2017;117(7):1230-1239. 
doi:10.1160/TH16-11-0876. 
3.  Pokorney SD, Piccini JP, Stevens SR, et al. Cause of Death and Predictors of 
All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial 
Fibrillation: Data From ROCKET AF. J Am Heart Assoc. 2016;5(3). 
doi:10.1161/JAHA.115.002197. 
4.  Marijon E, Le Heuzey J-Y, Connolly S, et al. Causes of death and influencing 
factors in patients with atrial fibrillation: a competing-risk analysis from the 
randomized evaluation of long-term anticoagulant therapy study. Circulation. 
2013;128(20):2192-2201. doi:10.1161/CIRCULATIONAHA.112.000491. 
5.  Fauchier L, Villejoubert O, Clementy N, et al. Causes of Death and Influencing 
Factors in Patients with Atrial Fibrillation. Am J Med. 2016;129(12):1278-1287. 
doi:10.1016/j.amjmed.2016.06.045. 
6.  Proietti M, Laroche C, Nieuwlaat R, et al. Increased burden of comorbidities 
and risk of cardiovascular death in atrial fibrillation patients in Europe over ten 
years: A comparison between EORP-AF pilot and EHS-AF registries. Eur J 
Intern Med. 2018. doi:10.1016/j.ejim.2018.05.016. 
7.  Proietti M, Laroche C, Opolski G, et al. “Real-world” atrial fibrillation 
management in Europe: observations from the 2-year follow-up of the 
 20 
EURObservational Research Programme-Atrial Fibrillation General Registry 
Pilot Phase. Europace. 2017;19(5):722-733. doi:10.1093/europace/euw112. 
8.  Kirchhof P. The future of atrial fibrillation management: integrated care and 
stratified therapy. Lancet (London, England). 2017;390(10105):1873-1887. 
doi:10.1016/S0140-6736(17)31072-3. 
9.  Gallagher C, Elliott AD, Wong CX, et al. Integrated care in atrial fibrillation: a 
systematic review and meta-analysis. Heart. May 2017:heartjnl-2016-310952. 
doi:10.1136/heartjnl-2016-310952. 
10.  Lip GYH. The ABC pathway: an integrated approach to improve AF 
management. Nat Rev Cardiol. September 2017. 
doi:10.1038/nrcardio.2017.153. 
11.  Greene HL. Atrial fibrillation follow-up investigation of rhythm management - 
The AFFIRM study design. Am J Cardiol. 1997;79(9):1198-1202. 
doi:10.1016/S0002-9149(97)00082-9. 
12.  Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and 
rhythm control in patients with atrial fibrillation. N Engl J Med. 
2002;347(23):1825-1833. doi:10.1056/NEJMoa021328. 
13.  Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on 
cardiovascular disease prevention in clinical practice: The Sixth Joint Task 
Force of the European Society of Cardiology and Other Societies on 
Cardiovascular Disease Prevention in Clinical Practice (constituted by 
representati. Eur Heart J. May 2016. doi:10.1093/eurheartj/ehw106. 
14.  Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to 
prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern 
Med. 2007;146(12):857-867. doi:10.7326/0003-4819-146-12-200706190-
 21 
00007. 
15.  Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and prediction of 
adverse events in patients with atrial fibrillation: a systematic review. Circ 
Cardiovasc Qual Outcomes. 2008;1(2):84-91. 
doi:10.1161/CIRCOUTCOMES.108.796185. 
16.  Sandén P, Renlund H, Svensson PJ, Själander A. Bleeding complications and 
mortality in warfarin-treated VTE patients, dependence of INR variability and 
iTTR. Thromb Haemost. 2016;117(1):27-32. doi:10.1160/TH16-06-0489. 
17.  Sjögren V, Grzymala-Lubanski B, Renlund H, et al. Safety and efficacy of well 
managed warfarin. A report from the Swedish quality register Auricula. Thromb 
Haemost. 2015;113(6):1370-1377. doi:10.1160/TH14-10-0859. 
18.  Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa T-P. Risks of stroke 
and mortality associated with suboptimal anticoagulation in atrial fibrillation 
patients. Thromb Haemost. 2011;106(5):968-977. doi:10.1160/TH11-05-0353. 
19.  Kooistra HAM, Veeger NJGM, Khorsand N, Kluin-Nelemans HC, Meijer K, 
Piersma-Wichers M. Long-term quality of VKA treatment and clinical outcome 
after extreme overanticoagulation in 14,777 AF and VTE patients. Thromb 
Haemost. 2014;113(4):881-890. doi:10.1160/TH14-06-0537. 
20.  Haas S, ten Cate H, Accetta G, et al. Quality of Vitamin K Antagonist Control 
and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective 
from the GARFIELD-AF Registry. Garcia de Frutos P, ed. PLoS One. 
2016;11(10):e0164076. doi:10.1371/journal.pone.0164076. 
21.  Mazurek M, Huisman M, Rothman K, et al. Regional Differences in 
Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIA-AF 
Phase II Registry. Thromb Haemost. 2017;117(12):2376-2388. 
 22 
doi:10.1160/TH17-08-0555. 
22.  Raparelli V, Proietti M, Cangemi R, Lip GYHGYH, Lane DADA, Basili S. 
Adherence to oral anticoagulant therapy in patients with atrial fibrillation focus 
on non-vitamin k antagonist oral anticoagulants. Thromb Haemost. 
2017;117(2):209-218. doi:10.1160/TH16-10-0757. 
23.  Caldeira D, David C, Sampaio C. Rate versus rhythm control in atrial fibrillation 
and clinical outcomes: Updated systematic review and meta-analysis of 
randomized controlled trials. Arch Cardiovasc Dis. 2012;105(4):226-238. 
doi:10.1016/j.acvd.2011.11.005. 
24.  Chung MK, Shemanski L, Sherman DG, et al. Functional status in rate- versus 
rhythm-control strategies for atrial fibrillation: results of the Atrial Fibrillation 
Follow-Up Investigation of Rhythm Management (AFFIRM) Functional Status 
Substudy. J Am Coll Cardiol. 2005;46(10):1891-1899. 
doi:10.1016/j.jacc.2005.07.040. 
25.  Marrouche NF, Brachmann J, Andresen D, et al. Catheter Ablation for Atrial 
Fibrillation with Heart Failure. N Engl J Med. 2018;378(5):417-427. 
doi:10.1056/NEJMoa1707855. 
26.  Packer DL, Mark DB, Robb RA, et al. CATHETER ABLATION VS. 
ANTIARRHYTHMIC DRUG THERAPY FOR ATRIAL FIBRILLATION: THE 
RESULTS OF THE CABANA MULTICENTER INTERNATIONAL 
RANDOMIZED CLINICAL TRIAL. Hear Rhythm. 2018;15(6):940-941 Heart 
Rhythm Sessions Late-Breaking Trials. doi:10.1016/j.hrthm.2018.04.024. 
27.  Kim E-J, Yin X, Fontes JD, et al. Atrial fibrillation without comorbidities: 
Prevalence, incidence and prognosis (from the Framingham Heart Study). Am 
Heart J. 2016;177:138-144. doi:10.1016/j.ahj.2016.03.023. 
 23 
28.  Perera KS, Pearce LA, Sharma M, et al. Predictors of Mortality in Patients With 
Atrial Fibrillation (from the Atrial Fibrillation Clopidogrel Trial With Irbesartan for 
Prevention of Vascular Events [ACTIVE A]). Am J Cardiol. December 2017. 
doi:10.1016/j.amjcard.2017.11.028. 
29.  Proietti M, Raparelli V, Olshansky B, Lip GY. Polypharmacy and major adverse 
events in atrial fibrillation: observations from the AFFIRM trial. Clin Res 
Cardiol. 2016;105(5):412-420. doi:10.1007/s00392-015-0936-y. 
30.  Boriani G, Proietti M. Atrial fibrillation prevention: An appraisal of current 
evidence. Heart. 2018;104(11). doi:10.1136/heartjnl-2017-311546. 
31.  Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the 
management of atrial fibrillation developed in collaboration with EACTS. Eur 
Heart J. 2016;37(38):2893-2962. doi:10.1093/eurheartj/ehw210. 
32.  Kotecha D, Breithardt G, Camm AJ, et al. Integrating new approaches to atrial 
fibrillation management: the 6th AFNET/EHRA Consensus Conference. EP 
Eur. 2018;20(3):395-407. doi:10.1093/europace/eux318. 
  
 24 
FIGURE LEGENDS 
 
Figure 1: The ABC Pathway definitions applied to the AFFIRM Cohort 
Legend: Symptoms considered were: chest pain, diaphoresis, diuresis, dizziness, 
dyspnoea, oedema, fast heart rate, fatigue, orthopnoea, palpitations, panic, 
paroxysmal nocturnal dyspnoea, syncope, other symptoms; ACEi= angiotensin-
converting enzyme inhibitor; ßBs= beta-blockers; CAD= coronary artery disease; 
HF= heart failure; HTN= hypertension; LLD= lipid lowering drugs; PAD= peripheral 
artery disease; TIA= transient ischemic attack; TTR= time in therapeutic range. 
 
Figure 2: Kaplan-Meier Curves according to the Integrated Care use 
Legend: Solid Black Line= Integrated Care (ABC Group); Grey Dotted Line= non-
ABC Care. 
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Table 1: Baseline Characteristics according to the Use of Integrated Care 
 Non-ABC care 
 
N= 2947 
Integrated Care 
(ABC Group) 
N= 222 
p 
Age years, median [IQR] 70 [65-76] 70 [65-75] 0.302 
BMI kg/m2, median [IQR] 1978 28.2 [25.0-32.1] 28.0 [24.5-31.4] 0.236 
Female sex, n (%) 1177 (39.9) 60 (27.0) <0.001 
Hypertension, n (%) 2102 (71.3) 141 (63.5) 0.014 
Diabetes Mellitus, n (%) 589 (20.0) 36 (16.2) 0.173 
Smoking , n (%) 358 (12.1) 20 (9.0) 0.164 
Coronary Artery Disease, n (%) 1155 (39.2) 9 (4.1) <0.001 
Myocardial Infarction, n (%) 517 (17.5) 6 (2.7) <0.001 
Peripheral Arterial Disease, n (%) 200 (6.8) 2 (0.9) 0.001 
Stroke/TIA, n (%) 427 (14.5) 4 (1.8) <0.001 
Heart Failure, n (%) 678 (23) 6 (2.7) <0.001 
Valvular Heart Disease, n (%) 381 (12.9) 20 (9.0) 0.090 
Hepatic/Renal Disease, n (%) 148 (5) 10 (4.5) 0.733 
Pulmonary Disease, n (%) 404 (13.7) 23 (10.4) 0.159 
First AF Episode, n (%) 3083 938 (32.9) 78 (35.5) 0.446 
Randomized Treatment, n (%) 
Rate Control 
Rhythm Control 
 
1604 (54.4) 
1343 (45.6) 
 
123 (55.4) 
99 (44.6) 
0.778 
Use of Aspirin, n (%) 736 (25.0) 36 (16.2) 0.003 
Comorbidities, median [IQR] 2 [1-3] 1 [1-2] <0.001 
Polypharmacy, n (%) 3165 1173 (39.9) 49 (22.1) <0.001 
CHA2DS2-VASc, median [IQR] 3 [2-4] 2 [1-3] <0.001 
TTR %, median [IQR] 65.9 [49.9-79.8] 82.2 [76.1-89.3] <0.001 
 
Legend: AF= atrial fibrillation; BMI= body mass index; IQR= interquartile range; 
TIA= transient ischemic attack; TTR= time in therapeutic range. 
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Table 2: Outcomes rates according to the Use of Integrated Care 
 Non-ABC Care 
 
N= 2947 
Integrated Care 
(ABC Group) 
N= 222 
p 
All-Cause Death, n (%) 326 (11.1) 7 (3.2) <0.001 
Composite Outcome, n (%) 412 (14.0) 9 (4.1) <0.001 
Stroke, n (%) 111 (3.8) 6 (2.7) 0.418 
Major Bleeding, n (%) 178 (6.0) 3 (1.4) 0.004 
Cardiovascular Death, n (%) 185 (6.5) 2 (0.9) 0.001 
First Hospitalization, n (%) 1868 (63.4) 99 (44.6) <0.001 
First Cardiovascular 
Hospitalization, n (%) 
1088 (36.9) 48 (21.6) <0.001 
Multiple Hospitalizations, n (%) 1053 (35.7) 36 (16.2) <0.001 
Total Hospitalizations, median 
[IQR] 
1 [0-2] 0 [0-1] <0.001 
First Hospitalization Days, 
median [IQR] 
4 [2-8] 3 [2-7] <0.001 
Total Hospitalization Days, 
median [IQR] 
9 [4-18] 5 [2-11] <0.001 
 
Legend: IQR= interquartile range. 
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Table 3: Regression Models for the Use of Integrated Care in Relation to Outcomes 
 Integrated Care (ABC) vs. Non-ABC Care* 
 HR (95% CI)§ p 
All-Cause Death 0.35 (0.17-0.75) 0.006 
Composite Outcome 0.35 (0.18-0.68) 0.002 
Stroke 0.90 (0.39-2.06) 0.804 
Major Bleeding 0.26 (0.08-0.81) 0.021 
Cardiovascular Death 0.17 (0.04-0.70) 0.014 
First Hospitalization 0.65 (0.53-0.80) <0.001 
First Cardiovascular 
Hospitalization 
0.57 (0.43-0.77) <0.001 
 OR (95% CI)# p 
Multiple Hospitalizations 0.38 (0.26-0.56) <0.001 
 Std. Beta† p 
Total Hospitalizations -0.098 <0.001 
First Hospitalization Days -0.034 0.142 
Total Hospitalization Days -0.061 0.008 
 
Legend: *Adjusted for age, gender, diabetes mellitus, hepatic/renal disease, 
pulmonary disease, first AF episode, use of aspirin; §Cox regression model; 
#Logistic regression model; †Linear regression model; AF= atrial fibrillation; CI= 
confidence interval; HR= hazard ratio; OR= odds ratio. 
Table 4: Relationship between ABC Pathway Components and Outcomes 
 All-Cause 
Death* 
Composite 
Outcome* 
First 
Hospitalization* 
 HR (95% CI) HR (95% CI) HR (95% CI) 
Standard Care Ref. Ref. Ref. 
Only A-B Criteria 0.72 (0.48-
1.08) 
0.75 (0.53-1.07) 0.64 (0.54-0.75) 
 28 
Only B-C Criteria 0.64 (0.37-
1.09) 
0.68 (0.43-1.09) 0.77 (0.63-0.92) 
Only A-C Criteria 0.42 (0.24-
0.76) 
0.48 (0.31-0.77) 0.71 (0.60-0.85) 
Integrated Care (All 
ABC Criteria fulfilled) 
0.31 (0.15-
0.67) 
0.32 (0.16-0.62) 0.58 (0.47-0.71) 
  
Legend: *Adjusted for age, gender, diabetes mellitus, hepatic/renal disease, 
pulmonary disease, first AF episode, use of aspirin; CI= confidence interval; HR= 
hazard ratio. 
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Table 5: Relationship between Total Number of ABC Criteria Fulfilled and Outcomes 
 All-Cause 
Death* 
Composite 
Outcome* 
First 
Hospitalization* 
 HR (95% 
CI) 
HR (95% CI) HR (95% CI) 
No ABC Criteria 
fulfilled 
Ref. Ref. Ref. 
At least One ABC 
Criteria fulfilled 
0.70 (0.55-
0.90) 
0.73 (0.59-0.91) 0.73 (0.65-0.81) 
At least Two ABC 
Criteria fulfilled 
0.49 (0.35-
0.67) 
0.54 (0.40-0.71) 0.56 (0.50-0.64) 
Integrated Care (All 
ABC Criteria fulfilled) 
0.25 (0.12-
0.55) 
0.26 (0.13-0.52) 0.47 (0.38-0.59) 
  
Legend: *Adjusted for age, gender, diabetes mellitus, hepatic/renal disease, 
pulmonary disease, first AF episode, use of aspirin; CI= confidence interval; HR= 
hazard ratio.  
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Highlights  
 
• The ABC pathway streamlines integrated care of atrial fibrillation patients 
• Integrated care, according to ABC pathway, is associated with lower risk of 
adverse events. 
• There was lower mortality, stroke/bleeding/cardiovascular death and 
hospitalization. 
• Use of the ABC pathway allows holistic and integrated management of atrial 
fibrillation patients. 
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Figure 1 
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Figure 2 
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Table S1: Sensitivity Analysis for Patients with CHA2DS2-VASc ≥2 
 Integrated Care (ABC) vs. Non-ABC Care* 
 HR (95% CI)§ p 
All-Cause Death 0.37 (0.17-0.84) 0.017 
Composite Outcome 0.29 (0.13-0.65) 0.003 
Stroke 0.90 (0.39-2.06) 0.804 
Major Bleeding 0.26 (0.08-0.81) 0.021 
CV Death 0.17 (0.04-0.70) 0.014 
First Hospitalization 0.59 (0.46-0.75) <0.001 
First CV Hospitalization 0.55 (0.39-0.78) 0.001 
 OR (95% CI)# p 
Multiple Hospitalizations 0.39 (0.26-0.61) <0.001 
 Std. Beta† p 
Total Hospitalizations -0.095 <0.001 
First Hospitalization Days -0.037 0.131 
Total Hospitalization Days -0.059 0.015 
Legend: *Adjusted for age, gender, diabetes mellitus, hepatic/renal disease, 
pulmonary disease, first AF episode, use of aspirin; §Cox regression model; 
#Logistic regression model; †Linear regression model; AF= atrial fibrillation; CI= 
confidence interval; CV= cardiovascular; HR= hazard ratio; OR= odds ratio. 
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Figure S1: Kaplan-Meier about Stroke according to the type of care  
 
Legend: Log-Rank: 0.277, p=0.599  
 36 
Figure S2: Kaplan-Meier about Major Bleeding according to the type of care 
 
Legend: Log-Rank: 7.115, p=0.008  
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Figure S3: Kaplan-Meier about Cardiovascular Death according to the type of care  
 
Legend: Log-Rank: 8.394, p=0.004  
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Figure S4: Kaplan-Meier about First Cardiovascular Hospitalization according to the 
type of care  
 
Legend: Log-Rank: 16.876, p<0.001  
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Figure S5: Kaplan-Meier about All-cause death according to level of integrated care 
 
Legend: Log-Rank: 30.642, p<0.001 
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Figure S6: Kaplan-Meier about Composite outcome according to level of integrated 
care 
Legend: Log-Rank: 37.252, p<0.001 
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Figure S7: Kaplan-Meier about First hospitalization according to level of integrated 
care 
Legend: Log-Rank: 83.125, p<0.001 
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Figure S8: Kaplan-Meier about All-cause death according amount of ABC criteria 
Legend: Log-Rank: 43.485, p<0.001 
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Figure S9: Kaplan-Meier about Composite outcome according amount of ABC 
criteria 
Legend: Log-Rank: 52.907, p<0.001 
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Figure S10: Kaplan-Meier about First hospitalization according amount of ABC 
criteria 
Legend: Log-Rank: 131.967, p<0.001 
 
